Cover Image

The impact of diabetes and osteoarthritis on the occurrence of stroke, acute myocardial infarction, and heart failure among older adults with non-valvular atrial fibrillation in Hawaii: a retrospective observational cohort study

Abstract Background To date, little is known about cardiovascular disease risks among older adults with non-valvular atrial fibrillation by their association with diabetes and osteoarthritis status, based on longitudinal data with substantial amounts of non-white individuals. The objective of this s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Masako Matsunaga (Author), John J. Chen (Author), Mayumi Jijiwa (Author), Eunjung Lim (Author)
Format:	Book
Published:	BMC, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS' VIEWPOINT
by: E. A. Drozdova
Published: (2015)

SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS' VIEWPOINT
by: E. A. Drozdova
Published: (2015)

Risk Factors Associated with Cardioembolic Stroke in Patients with non Valvular Atrial Fibrillation
by: Daniel Guerra García, et al.
Published: (2018)

Risk Factors Associated with Cardioembolic Stroke in Patients with non Valvular Atrial Fibrillation
by: Daniel Guerra García, et al.
Published: (2018)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012)

ATRIAL FIBRILLATION ASSOCIATED WITH MYOCARDIAL INFARCTION OF DIFFERENT LOCALIZATIONS
by: R. Bhattarai, et al.
Published: (2015)

ATRIAL FIBRILLATION ASSOCIATED WITH MYOCARDIAL INFARCTION OF DIFFERENT LOCALIZATIONS
by: R. Bhattarai, et al.
Published: (2015)

Effect of Rivaroxaban in Stroke Prevention in Patient with Atrial Fibrillation due to Valvular Heart Disease
by: Waqar shamim, et al.
Published: (2022)

Is There Association Between Changes in eGFR Value and the Risk of Permanent Type of Atrial Fibrillation? - Analysis of Valvular and Non-Valvular Atrial Fibrillation Population
by: Elzbieta Mlodawska, et al.
Published: (2014)

Atrial fibrillation-related acute myocardial infarction and acute mesenteric ischemia
by: Levent Pay, et al.
Published: (2021)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
by: Yu-Sheng Lin, et al.
Published: (2021)

Shensong Yangxin capsule reduces atrial fibrillation susceptibility by inhibiting atrial fibrosis in rats with post-myocardial infarction heart failure
by: Ma J, et al.
Published: (2018)

USP38 exacerbates atrial inflammation, fibrosis, and susceptibility to atrial fibrillation after myocardial infarction in mice
by: Yang Gong, et al.
Published: (2023)

Evaluation of risk factors and drug adherence in the occurrence of stroke in patients with atrial fibrillation
by: Maya Hajj, et al.
Published: (2020)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015)

The Utility of Speckle Tracking Echocardiographic Parameters in Predicting Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Non-Valvular Atrial Fibrillation
by: Zeng D, et al.
Published: (2024)

Total Bilirubin Level is Associated with the Risk of Left Atrial Appendage Thrombosis in Patients with Non-Valvular Atrial Fibrillation
by: Weihao Meng, et al.
Published: (2022)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015)

NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
by: E. P. Panchenko
Published: (2015)

Stroke, Dementia and Atrial Fibrillation
Published: (2020)

Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice
by: K. G. Pereverzeva, et al.
Published: (2019)

De Novo Atrial Fibrillation Increases Intra-hospital Mortality in Myocardial Infarction with ST Elevation?
by: Ailed Elena Rodríguez Jiménez, et al.
Published: (2017)

De Novo Atrial Fibrillation Increases Intra-hospital Mortality in Myocardial Infarction with ST Elevation?
by: Ailed Elena Rodríguez Jiménez, et al.
Published: (2017)

Association of common genetic variants related to atrial fibrillation and the risk of ventricular fibrillation in the setting of first ST-elevation myocardial infarction
by: Reza Jabbari, et al.
Published: (2017)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015)

Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
by: Daria Generalova, et al.
Published: (2020)

Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
by: Isabella C DENARDIN, et al.
Published: (2021)

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020)

Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation
by: A. S. Kolbin, et al.
Published: (2023)

Paroxysmal atrial fibrillation in cryptogenic stroke
by: Neha S Dangayach, et al.
Published: (2011)

Real-world outcomes of anticoagulant prescription in anticoagulant-naïve octogenarian patients with non-valvular atrial fibrillation
by: Sugeon Park, et al.
Published: (2020)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
by: V. A. Ionin, et al.
Published: (2021)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015)